Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Academic Article

abstract

• Monthly intravenous cyclophosphamide treatment was compared with placebo treatment for one year in a controlled trial of 14 patients with relapsing/remitting multiple sclerosis. Eight patients received placebo and six patients received cyclophosphamide. The cyclophosphamide group showed a definite trend to have less frequent and less prolonged episodes than the placebo group. When each group served as their own controls, the cyclophosphamide group had a significant decrease in episodes while the placebo group did not. When the placebo group was then given cyclophosphamide, they also had a significant decrease in episodes. When all patients who were receiving cyclophosphamide were combined for analysis, the decrease in episodes was even more evident. Complications were minimal. These results suggest that monthly intravenous doses of cyclophosphamide may influence the frequency and duration of episodes of relapsing/remitting multiple sclerosis.

authors

• Huston, David

published proceedings

• Arch Neurol

altmetric score

• 3

author list (cited authors)

• Killian, J. M., Bressler, R. B., Armstrong, R. M., & Huston, D. P.

citation count

• 51

complete list of authors

• Killian, JM||Bressler, RB||Armstrong, RM||Huston, DP

publication date

• January 1988

publisher

• American Medical Association (AMA)  Publisher

published in

• Archives of Neurology  Journal

keywords

• Adult
• Clinical Trials As Topic
• Cyclophosphamide
• Double-Blind Method
• Drug Administration Schedule
• Female
• Humans
• Male
• Multiple Sclerosis
• Pilot Projects
• Random Allocation
• T-Lymphocytes

PubMed Central ID

• 3276298

Digital Object Identifier (DOI)

• 10.1001/archneur.1988.00520250033014

start page

• 27

end page

• 30

volume

• 45

issue

• 1

URL

• http://dx.doi.org/10.1001/archneur.1988.00520250033014